Spyre Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2021 | $-53.7M | $-54.3M | $573.0K | $8.0M |
| FY2022 | $-80.1M | $-80.2M | $38.0K | $7.1M |
| FY2023 | $-99.9M | $-99.9M | $0 | $25.7M |
| FY2024 | $-157.4M | $-157.4M | $0 | $44.8M |
| FY2025 | $-169.3M | $-169.3M | — | $37.6M |